Charles River and Medigen Advance Vaccine Development With NGS
Wilmington, Massachusetts, August 20, 2026 Charles River Laboratories International and Medigen Vaccine Biologics Corp. (MVC) have entered into a...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Wilmington, Massachusetts, August 20, 2026 Charles River Laboratories International and Medigen Vaccine Biologics Corp. (MVC) have entered into a...
SUZHOU, China, May 26, 2026 WuXi Vaccines, a wholly owned subsidiary of WuXi Biologics specializing in vaccine Contract Development...
